Innomedica OÜ

Innomedica OÜ is conducting research in cardiovascular diseases, focusing on atherosclerotic cardiovascular disease and elevated lipoprotein(a). The studies are designed to assess whether new treatment approaches can reduce major heart-related events and improve long-term outcomes for people at higher cardiovascular risk.

• Evaluating a new therapy for lowering the risk of serious cardiovascular events
• Studying ASCVD and lipoprotein(a) as key targets in heart disease research
• Comparing treatment effects against placebo to understand protection from heart attack and related complications

This work reflects a strong focus on prevention and outcome improvement in cardiology, with attention to patients who may benefit from more effective risk reduction strategies.

The site is also involved in digestive system disease research, particularly for moderately to severely active ulcerative colitis. The trial activity in this area is aimed at improving disease control and helping more patients achieve clinical remission through new treatment options.

• Testing a potential therapy for ulcerative colitis
• Assessing whether treatment can improve signs and symptoms of active intestinal inflammation
• Supporting research into better ways to achieve and maintain remission in gastroenterology

These studies contribute to a broader effort to expand treatment choices for people living with chronic inflammatory bowel disease.

In the area of skin and connective tissue diseases, Innomedica OÜ is participating in research on psoriatic arthritis. The trials are focused on understanding long-term safety, tolerability, and effectiveness of treatment for adults with active disease.

• Monitoring long-term safety and tolerability in psoriatic arthritis
• Evaluating whether treatment can maintain symptom control over time
• Exploring outcomes that matter to patients with chronic inflammatory joint and skin disease

This research supports advances in rheumatology and dermatology, with a practical focus on sustained disease management and quality of life.